Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

research and development ("R&D") programs and selling, general and administrative ("SG&A") activities to support recent growth were more than offset by higher revenues compared to 2009. On a US GAAP basis, operating income increased by $64 million, or 70%, to $156 million (2009: $92 million). US GAAP operating income in Q3 2010 also included an up-front payment of $45 million made to Acceleron Pharma Inc. ("Acceleron") in relation to the collaboration for activin receptor type IIB ("ActRIIB") molecules and impairment charges of $43 million following the decision to divest DAYTRANA(R) to Noven Pharmaceuticals Inc. ("Noven"). - Cash generation, which is a Non GAAP measure, increased by $51 million to $271 million (2009: $220 million). Higher cash receipts from product sales and royalties were partially offset by higher cash payments on the increased investment in R&D and SG&A, and the timing of sales deduction payments in 2010. - Net debt at September 30, 2010 was $309 million (December 31, 2009: $615 million), a reduction of $306 million in the year to date. Strong cash generation of $959 million in the nine months to September 30, 2010 has reduced net debt as well as funded the acquisition of and construction at Lexington Technology Park, cash tax payments and the upfront payment made to Acceleron. Excluding restricted cash of $584 million held to pay for the acquisition of Movetis NV ("Movetis") in the fourth quarter, net debt at September 30, 2010 was $893 million.

2010 OUTLOOK

Following a stronger than expected third quarter, we have increased our expectations for the full year 2010. We now expect to see Non GAAP earnings per ADS of up to $4.20. This increase includes the financial effect of the Movetis acquisition and the disposal of DAYTRANA on October 1, 2010; it also includes the cumulative impact of US Healthcare Reform, mandated European price cuts and adverse foreign exchange rates.

The strong growth of our core p
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Jan. 26, 2012 Amgen (NASDAQ: AMGN ... today announced that the companies have entered into a ... a biotechnology company founded in Germany with its research ... Rockville, Md., for $11 per share in cash. The ...
... 2012 Sequenom, Inc. (NASDAQ: SQNM ) today ... shares of its common stock, including 1,950,000 shares sold pursuant ... to the underwriters. All of the shares were offered by ... share. The gross proceeds to Sequenom from this offering were ...
... Novartis Pharmaceuticals Corporation (NPC) and Sanford Wittels & Heisler, LLP, ... agreement to resolve the nationwide Wage and Hour class action ... the Southern District of New York.  NPC ... payment of up to 99 million dollars for eligible class ...
Cached Biology Technology:Amgen to Acquire Micromet 2Amgen to Acquire Micromet 3Amgen to Acquire Micromet 4Amgen to Acquire Micromet 5Amgen to Acquire Micromet 6Amgen to Acquire Micromet 7Amgen to Acquire Micromet 8Amgen to Acquire Micromet 9Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 2Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 2Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 4
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... years ago, Katia Silvera , a postdoctoral scholar at ... a field trip in a mountainous area in central Panama ... before. , Unable to identify it, they contacted German Carnevali, ... to be an unnamed species. So Carnevali recently named it ... the genus name, comprising about 40 species in the world. ...
(Date:4/17/2014)... deforestation and fragmentation of forests in the Amazon ... forests, contributing to rapid and widespread forest loss ... researchers., The findings show that forests in the ... droughts coupled with forest fires lead to large-scale ... Jennifer Balch, assistant professor of geography, Penn State. ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3
... University of Illinois have developed a new, more accurate ... that results from changes in land use. The ... Biology , takes into account many factors not included ... is an urgent need to accurately assess whether particular ...
... delivering oxygen to our vital organs are obstructed by atherosclerosis ... attack or damage to a peripheral tissue such as the ... injury or destruction from a choked-off blood supply varies from ... whose circulatory system has the best back-up plan to provide ...
... A Montreal study finds heterotrophic bacteria counts, in ... the recommended limits specified by the United States Pharmacopeia ... today at the 110th General Meeting of the American ... the cleanest tap water a large number of urban ...
Cached Biology News:Researchers calculate the greenhouse gas value of ecosystems 2Researchers calculate the greenhouse gas value of ecosystems 3Study pinpoints new role of molecule in the health of body's back-up blood circulation 2Study pinpoints new role of molecule in the health of body's back-up blood circulation 3Study pinpoints new role of molecule in the health of body's back-up blood circulation 4Study finds high level of bacteria in bottled water in Canada 2
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
... 53 new primer sets added in Dec 2005 ... 3 hours , Detection from as ... , Specific primers available for hundreds of ... real-time or end-point RT-PCR , Ideal ...
AGAROSE PREP, 50G, 1 EA. Category: Genephor Precast Gels....
Biology Products: